| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T162 |
0-20 |
Sentence |
denotes |
Author Contributions |
| T163 |
21-274 |
Sentence |
denotes |
Conceptualization, M.H., A.A., and A.C.; writing—original draft preparation, A.A., A.C., M.H., F.L.v.d.V., J.D.J., C.L.-F., P.K., O.A.C., D.S.P., R.K.; writing—review and editing, M.H., A.A., A.C., F.L.v.d.V., J.D.J., C.L.-F., P.K., O.A.C., D.S.P., R.K. |
| T164 |
275-351 |
Sentence |
denotes |
All authors have read and agreed to the published version of the manuscript. |
| T165 |
353-360 |
Sentence |
denotes |
Funding |
| T166 |
361-721 |
Sentence |
denotes |
AC was supported by the Fundação para a Ciência e a Tecnologia (FCT) (CEECIND/03628/2017, UIDB/50026/2020 and UIDP/50026/2020), and the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) (NORTE-01-0145-FEDER-000013 and NORTE-01-0145-FEDER-000023). |
| T167 |
722-771 |
Sentence |
denotes |
This research received no other external funding. |
| T168 |
773-794 |
Sentence |
denotes |
Conflicts of Interest |
| T169 |
795-847 |
Sentence |
denotes |
M.H. received research funding by Gilead and Pfizer. |
| T170 |
848-985 |
Sentence |
denotes |
D.S.P. receives research support and/or serves on advisory boards for Amplyx, Cidara, Scynexis, N8 Medical, Merck, Regeneron, and Pfizer. |
| T171 |
986-1487 |
Sentence |
denotes |
P.K. has received non-financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany, and is an adivisor to, or received lecture honoraria from Akademie für Infektionsmedizin e.V., Astellas Pharma, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, NOXXON Pharma NV., and University Hospital, LMU Munich outside the submitted work. |
| T172 |
1488-2341 |
Sentence |
denotes |
O.A.C. is supported by the German Federal Ministry of Research and Education; is funded by the Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany’s Excellence Strategy (CECAD, EXC 2030 - 390661388); has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, MedPace, Melinta Therapeutics, MSD, Pfizer, and Scynexis; is a consultant to Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini Ricerche, Roche Diagnostics, MSD, Nabriva Therapeutics, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, and Vical; and received lecture honoraria from Astellas, Basilea, Gilead, Grupo Biotoscana, MSD, and Pfizer. |
